Literature DB >> 25107282

The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.

Jordy van Enkhuizen1, David S Janowsky2, Berend Olivier3, Arpi Minassian2, William Perry2, Jared W Young4, Mark A Geyer5.   

Abstract

Bipolar disorder is a unique illness characterized by fluctuations between mood states of depression and mania. Originally, an adrenergic-cholinergic balance hypothesis was postulated to underlie these different affective states. In this review, we update this hypothesis with recent findings from human and animal studies, suggesting that a catecholaminergic-cholinergic hypothesis may be more relevant. Evidence from neuroimaging studies, neuropharmacological interventions, and genetic associations support the notion that increased cholinergic functioning underlies depression, whereas increased activations of the catecholamines (dopamine and norepinephrine) underlie mania. Elevated functional acetylcholine during depression may affect both muscarinic and nicotinic acetylcholine receptors in a compensatory fashion. Increased functional dopamine and norepinephrine during mania on the other hand may affect receptor expression and functioning of dopamine reuptake transporters. Despite increasing evidence supporting this hypothesis, a relationship between these two neurotransmitter systems that could explain cycling between states of depression and mania is missing. Future studies should focus on the influence of environmental stimuli and genetic susceptibilities that may affect the catecholaminergic-cholinergic balance underlying cycling between the affective states. Overall, observations from recent studies add important data to this revised balance theory of bipolar disorder, renewing interest in this field of research.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetylcholine; Bipolar disorder; Depression; Dopamine; Mania; Mice

Mesh:

Substances:

Year:  2014        PMID: 25107282      PMCID: PMC4318788          DOI: 10.1016/j.ejphar.2014.05.063

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  171 in total

1.  Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy.

Authors:  R J Steingard; D A Yurgelun-Todd; J Hennen; J C Moore; C M Moore; K Vakili; A D Young; A Katic; W R Beardslee; P F Renshaw
Journal:  Biol Psychiatry       Date:  2000-12-01       Impact factor: 13.382

2.  Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder.

Authors:  Dara M Cannon; Richard E Carson; Allison C Nugent; William C Eckelman; Dale O Kiesewetter; Joan Williams; Denise Rollis; Michele Drevets; Shilpa Gandhi; Gerardo Solorio; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-07

3.  The amphetamine-chlordiazepoxide mixture, a pharmacological screen for mood stabilizers, does not enhance amphetamine-induced disruption of prepulse inhibition.

Authors:  Tessa N Douma; Adam Kolarz; Ynte Postma; Berend Olivier; Lucianne Groenink
Journal:  Behav Brain Res       Date:  2011-07-26       Impact factor: 3.332

4.  Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania.

Authors:  Jared W Young; Jordy van Enkhuizen; Catharine A Winstanley; Mark A Geyer
Journal:  J Psychopharmacol       Date:  2011-03-18       Impact factor: 4.153

5.  Attenuation of some subjective effects of amphetamine following tyrosine depletion.

Authors:  S F McTavish; M H McPherson; T Sharp; P J Cowen
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

Review 6.  The role of dopamine in bipolar disorder.

Authors:  David A Cousins; Kelly Butts; Allan H Young
Journal:  Bipolar Disord       Date:  2009-12       Impact factor: 6.744

Review 7.  Reverse translational strategies for developing animal models of bipolar disorder.

Authors:  Oz Malkesman; Daniel R Austin; Guang Chen; Husseini K Manji
Journal:  Dis Model Mech       Date:  2009 May-Jun       Impact factor: 5.758

8.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

Authors:  Carlos A Zarate; Jennifer L Payne; Jaskaran Singh; Jorge A Quiroz; David A Luckenbaugh; Kirk D Denicoff; Dennis S Charney; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2004-07-01       Impact factor: 13.382

9.  Mania-like behavior induced by disruption of CLOCK.

Authors:  Kole Roybal; David Theobold; Ami Graham; Jennifer A DiNieri; Scott J Russo; Vaishnav Krishnan; Sumana Chakravarty; Joseph Peevey; Nathan Oehrlein; Shari Birnbaum; Martha H Vitaterna; Paul Orsulak; Joseph S Takahashi; Eric J Nestler; William A Carlezon; Colleen A McClung
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-22       Impact factor: 11.205

10.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.

Authors:  Dawn D Han; Howard H Gu
Journal:  BMC Pharmacol       Date:  2006-03-03
View more
  32 in total

Review 1.  Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-08-19       Impact factor: 8.989

2.  Metabolomics Analyses of 14 Classical Neurotransmitters by GC-TOF with LC-MS Illustrates Secretion of 9 Cell-Cell Signaling Molecules from Sympathoadrenal Chromaffin Cells in the Presence of Lithium.

Authors:  Vivian Hook; Tobias Kind; Sonia Podvin; Mine Palazoglu; Carol Tran; Thomas Toneff; Stephanie Samra; Christopher Lietz; Oliver Fiehn
Journal:  ACS Chem Neurosci       Date:  2019-01-23       Impact factor: 4.418

Review 3.  Investigating the mechanism(s) underlying switching between states in bipolar disorder.

Authors:  Jared W Young; Davide Dulcis
Journal:  Eur J Pharmacol       Date:  2015-03-23       Impact factor: 4.432

4.  Omega-3 fatty acids and mood stabilizers alter behavioral and oxidative stress parameters in animals subjected to fenproporex administration.

Authors:  Lara M Gomes; Milena Carvalho-Silva; Letícia J Teixeira; Joyce Rebelo; Isabella T Mota; Rafaela Bilesimo; Monique Michels; Camila O Arent; Edemilson Mariot; Felipe Dal-Pizzol; Giselli Scaini; João Quevedo; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2016-12-16       Impact factor: 3.584

5.  The catecholaminergic neurotransmitter system in methylmercury-induced neurotoxicity.

Authors:  Marcelo Farina; Michael Aschner; João Batista Teixeira da Rocha
Journal:  Adv Neurotoxicol       Date:  2017-09-01

6.  Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features.

Authors:  Jordy van Enkhuizen; Morgane Milienne-Petiot; Mark A Geyer; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2015-07-05       Impact factor: 4.530

7.  Mice with reduced DAT levels recreate seasonal-induced switching between states in bipolar disorder.

Authors:  Jared W Young; Zackary A Cope; Benedetto Romoli; Esther Schrurs; Jordy van Enkhuizen; Richard F Sharp; Davide Dulcis
Journal:  Neuropsychopharmacology       Date:  2018-02-27       Impact factor: 7.853

8.  Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review.

Authors:  Katherine E McDonell; Cyndya A Shibao; Italo Biaggioni; Adam Hartman; David Robertson; Daniel O Claassen
Journal:  Cogn Behav Neurol       Date:  2019-09       Impact factor: 1.600

Review 9.  Dopamine in psychiatry: a historical perspective.

Authors:  Paul Bernard Foley
Journal:  J Neural Transm (Vienna)       Date:  2019-02-13       Impact factor: 3.575

Review 10.  Targeting Mitochondrial Dysfunction for Bipolar Disorder.

Authors:  Maya Kuperberg; Sophie L A Greenebaum; Andrew A Nierenberg
Journal:  Curr Top Behav Neurosci       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.